Adma Biologics Inc (NASDAQ:ADMA) has a beta value of 0.60 and has seen 0.4 million shares traded in the recent trading session. The company, currently valued at $4.95B, closed the recent trade at $20.77 per share which meant it gained $1.13 on the day or 5.75% during that session. The ADMA stock price is -13.82% off its 52-week high price of $23.64 and 70.2% above the 52-week low of $6.19. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.36 million shares traded. The 3-month trading volume is 3.04 million shares.
The consensus among analysts is that Adma Biologics Inc (ADMA) is Buy stock at the moment, with a recommendation rating of 1.50. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.14.
Adma Biologics Inc (NASDAQ:ADMA) trade information
Sporting 5.75% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ADMA stock price touched $20.77 or saw a rise of 6.65%. Year-to-date, Adma Biologics Inc shares have moved 21.11%, while the 5-day performance has seen it change -0.67%. Over the past 30 days, the shares of Adma Biologics Inc (NASDAQ:ADMA) have changed 4.90%. Short interest in the company has seen 12.96 million shares shorted with days to cover at 3.58.
Wall Street analysts have a consensus price target for the stock at $16, which means that the shares’ value could drop -29.81% from the levels at last check today.. The projected low price target is $14.0 while the price target rests at a high of $18.0. In that case, then, we find that the latest price level in today’s session is 13.34% off the targeted high while a plunge would see the stock lose 32.6% from the levels at last check today..
Adma Biologics Inc (ADMA) estimates and forecasts
The company’s shares have gained 28.85% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 16.10%.
3 analysts offering their estimates for the company have set an average revenue estimate of 116.4M for the current quarter. 3 have an estimated revenue figure of 121.3M for the next ending quarter. Year-ago sales stood 81.88M and 107.19M respectively for this quarter and the next, and analysts expect sales will grow by 42.17% for the current quarter and 16.10% for the next.
Earnings growth for 2025 is a modest 45.61% while over the next 5 years, the company’s earnings are expected to increase by 30.55%.
ADMA Dividends
Adma Biologics Inc is expected to release its next earnings report on 2025-Mar-02 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Adma Biologics Inc (NASDAQ:ADMA)’s Major holders
Insiders own 2.59% of the company shares, while shares held by institutions stand at 87.97% with a share float percentage of 90.30%. Investors are also buoyed by the number of investors in a company, with Adma Biologics Inc having a total of 448.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 18.64 million shares worth more than $208.45 million. As of 2024-06-30, BLACKROCK INC. held 8.0221% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 14.52 million shares as of 2024-06-30. The firm’s total holdings are worth over $162.3 million and represent 6.2459% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . As of Mar 31, 2025 , the former fund manager holds about 6.13% shares in the company for having 14.62 shares of worth $303.17 million while later fund manager owns 7.0 shares of worth $145.22 million as of Dec 31, 2024 , which makes it owner of about 2.93% of company’s outstanding stock.
